Key Highlights

  • Betashares Global Healthcare Currency Hedged ETF (ASX:DRUG) held a fund size of $178.83 million across 59 underlying companies.
  • Healthcare accounts for 100.00 per cent of the sector allocation, compared with a category average of 24.34 per cent.
  • Johnson & Johnson is the top holding at 8.67 per cent, followed closely by Eli Lilly and Company.
  • The fund's final distribution of $0.312 per unit was well above the $0.034 and $0.027 per unit paid in the two immediately preceding periods, lifting the annual Yield to 3.85 per cent.

Betashares Global Healthcare Currency Hedged ETF (ASX:DRUG) is an ASX-listed fund that tracks the Nasdaq Global ex-Australia Healthcare Hedged NR AUD index, designed to capture the performance of global healthcare companies outside Australia while hedging currency exposure back to Australian dollars. The fund sits within the Equity World Other Morningstar category, with a fund size of $178.83 million, 19,870,455 units on issue and a management fee of 0.57 per cent.

Sector Composition

DRUG's sector allocation is entirely concentrated in healthcare, which represents 100.00 per cent of the fund, compared with a category average of 24.34 per cent, reflecting the fund's single-sector mandate. No other sector carries an allocation within the current portfolio.

By market capitalisation, companies above $1 billion make up 100.00 per cent of the fund, above the category average of 92.52 per cent, with no exposure to companies below that threshold. The asset mix is entirely equities, with no cash, bond or other asset exposure recorded.

Top Holdings

DRUG holds 59 companies, with its top 10 positions accounting for 52.43 per cent of the fund and a Turnover ratio of 10.15 per cent. Johnson & Johnson is the largest holding at 8.67 per cent, followed by Eli Lilly and Company at 8.35 per cent and AbbVie at 6.70 per cent. UnitedHealth Group holds a 5.69 per cent weighting, Roche Holding 4.95 per cent, Merck & Co 4.16 per cent, Novartis 3.99 per cent, AstraZeneca 3.86 per cent, Thermo Fisher Scientific 3.11 per cent and Amgen 2.91 per cent.

Geographic Exposure

The United States dominates geographic exposure at 70.79 per cent, above the category average of 42.81 per cent. Switzerland contributes 11.71 per cent, the United Kingdom 6.38 per cent, Japan 2.97 per cent, France 2.67 per cent, Denmark 2.78 per cent, Germany 0.90 per cent, China 1.02 per cent, Belgium 0.53 per cent and Brazil 0.18 per cent.

Distribution and Risk Metrics

DRUG reported a Beta of 0.40 and a Standard Deviation of 13.39, among the lower Volatility readings across comparable funds. Its most recent final distribution was $0.312 per unit, with an ex-date of 1 July 2026, producing an annual yield of 3.85 per cent. This distribution was considerably higher than the $0.034 per unit paid in January 2026 and the $0.027 per unit paid in January 2025, though below the $0.223 per unit distributed in July 2024. The fund's ISIN is AU00000DRUG1.

Conclusion

Betashares Global Healthcare Currency Hedged ETF (ASX:DRUG) provides concentrated exposure to global pharmaceutical, biotechnology and healthcare services companies, with currency hedging applied back to Australian dollars. Its portfolio is weighted toward large, established businesses domiciled predominantly in the United States, and its most recent distribution rose markedly compared with the two immediately preceding payments.